Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs

(NASDAQ: CYRX) Cryoport, Inc. announced that Cryoport Systems' IntegriCell cryopreservation services have been selected by Verismo Therapeutics to support its lead candidates SynKIR™-110 and SynKIR™-310. Both candidates are in human clinical trials with initial Phase 1 data presented at the American Association for Cancer Research (AACR) 2026 Annual Meeting. IntegriCell will support cryopreservation for SynKIR™-110, currently being evaluated in the STAR-101 Phase 1 trial in patients with advanced mesothelin-expressing solid tumors, and SynKIR™-310, currently being evaluated in the CELESTIAL-301 Phase 1 trial in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. IntegriCell's cryopreservation service centers are strategically located in Houston, Texas and Liège, Belgium, providing geographic coverage to support clinical and commercial programs across the Americas and Europe. Verismo Therapeutics is a subsidiary of HLB Innovation, and its assets SynKIR™-110 (NCT05568680) and SynKIR™-310 (NCT06544265) are currently in Phase 1 clinical trials. Cryoport Systems further supports the availability of high-quality allogeneic starting materials through its strategic alliance with Gulf Coast Regional Blood Center. The company projects continued support for Verismo as their programs continue to advance.